 | 07/29/2010 09:40:14 PM
Kentucky Issues Solicitation for Legal Services to Assist with Investigation of Pharmaceutical Company
The state of Kentucky issued the following solicitation notice for the Office of Attorney General: Solicitation: 1100000034. Solicitation Type: Request for Proposals. Status: Open. Description: Legal ser to assist w/investigation of pharmaceutical co. Issued Date: 7/28/2010. Closing Date: 8/9/2010. Closing Time: 16:30. Time Left: 11 Days, 9 Hours. Requesting Office: Capital Bldg., Suite 34.
[Targeted News Service] |
| 07/29/2010 08:37:45 PM
Biowest Reports Fiscal 2010 Financial Results
BioWest Therapeutics Inc. , announced today the financial results for its fiscal year and fourth quarter ended April 30, 2010 and provided a corporate update. Non-dilutive Financing Transaction: On March 19, 2010, MIGENIX Inc. completed a corporate reorganization, pursuant to which it received gross cash proceeds of $4,000,000.
[Filing Services Canada] |
| 07/29/2010 08:35:28 PM
AstraZeneca boosted by results and US green light for heart drug: UK group reports $2bn net profit for quarter Blood-thinner Brilinta tipped as new blockbuster
AstraZeneca investors received a double dose of good news yesterday as the UK's second-largest pharmaceutical company revealed better-than-expected quarterly results and won US expert endorsement for its blood-thinning treatment Brilinta.
[Guardian (UK)] |
| 07/29/2010 08:01:19 PM
WuXi PharmaTech Well Positioned to Continue Growing as Independent Company; Will Receive Breakup Fee of $30 million
SHANGHAI, July 29 WuXi PharmaTech Inc. announced today that its previously announced transaction with Charles River Laboratories International Inc. has been terminated by mutual agreement due to Charles River shareholder opposition. "WuXi's strategy has not changed. "All of our businesses are performing very well," Dr. Li continued.
[PR Newswire US] |
| 07/29/2010 08:00:00 PM
Charles River Announces Mutual Termination of Acquisition Agreement with WuXi PharmaTech
- Board of Directors Approves $500 Million Stock Repurchase Plan - - Special Stockholder Meeting Canceled - - Second-Quarter Earnings Release and Conference Call Rescheduled - WILMINGTON, Mass.
[Business Wire] |
| 07/29/2010 06:32:39 PM
County revises pharmaceutical collection program
July 29--La Crosse County's Solid Waste Department is changing its pharmaceutical collection program after learning it might not meet federal guidelines. "It was brought to our attention in May that our program, which has operated successfully since 2007, may not be in alignment with interpretations specific to controlled substances," according to County Solid Waste Manager Randy Nedrelo.
[La Crosse Tribune (WI)] |
| 07/29/2010 06:30:06 PM
Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
SAN DIEGO, July 29 Orexigen® Therapeutics, Inc. announced that results from its COR-I trial of Contrave® were published online today in the journal Lancet. Many patients with obesity are at higher risk for diabetes and cardiovascular disease, so evaluating the impact of weight loss on markers of cardiovascular and metabolic risk was a key objective of the COR Phase 3 program.
[PR Newswire US] |
| 07/29/2010 05:48:06 PM
Actient Pharmaceuticals, LLC Closes Transaction to License and Acquire Specialty Pharmaceutical Products from UCB, INC.
Actient Pharmaceuticals, LLC, a portfolio company of GTCR, announced today the company successfully completed a transaction to license and acquire six pharmaceutical products from UCB, Inc., a subsidiary of UCB SA, an international biopharmaceutical company based in Brussels, Belgium.
[Business Wire] |
| 07/29/2010 05:44:02 PM
Curaxis Pharmaceutical Corp. Announces Completion of Reverse Merger With Auto Search Cars, Inc.
Curaxis Pharmaceutical Corp. is pleased to announce the completion of its reverse merger with Auto Search Cars, Inc.. The effective date of the Merger is July 29, 2010. In connection with the Merger, Auto Search is in the process of changing its name to Curaxis Pharmaceutical Corporation and expects the name change to be completed Friday, July 30th.
[GlobeNewswire] |
| 07/29/2010 05:24:35 PM
H.B. Fuller Adhesives Earn NSF Certification
ST. PAUL, Minn., July 29 H.B. Fuller Company, a leading global adhesives provider, has received notification from NSF International that two of its potting compounds for hollow fiber water filtration have been tested and certified by NSF to NSF/ANSI Standard 61 - Drinking Water System Components - Health Effects.
[PR Newswire US] |
| 07/29/2010 05:09:09 PM
Inhibitex to Host Conference Call to Report Second Quarter Financial Results on August 10, 2010
Inhibitex, Inc. announced today that it will host a conference call on Tuesday, August 10, 2010 at 9:00 a.m. EDT to review the Company's second quarter financial results and provide an update on recent corporate developments. Webcast Information. To access the conference call, please dial 407-9210 or 689-8049. About Inhibitex.
[Business Wire] |
| 07/29/2010 05:00:12 PM
Nuvo Research announces 2010 second quarter financial results
MISSISSAUGA, ON, July 29 Nuvo Research Inc., a drug development company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the quarter ended June 30, 2010.
[PR Newswire US] |
| 07/29/2010 05:00:08 PM
Nuvo Research announces 2010 second quarter financial results
Nuvo Research Inc., a drug development company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the quarter ended June 30, 2010.
[Canada Newswire] |
| 07/29/2010 04:53:50 PM
PediatRx Acquires Granisol(TM)
FIRST ACQUISITION FOR SPECIALTY PHARMACEUTICAL COMPANY.
[PR Newswire US] |
| 07/29/2010 04:44:14 PM
Novartis Vaccines Begins Shipment of Seasonal Influenza Vaccine Fluvirin(R) to U.S. Market to Help Protect Ahead of 2010-2011 Flu Season
07/29/10 -- Novartis Vaccines.
[Market Wire] |
| |
previous
|
next |
